TG Therapeutics (TGTX) News Today → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free TGTX Stock Alerts $16.57 +0.02 (+0.12%) (As of 09:13 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 18 at 7:25 AM | marketbeat.comThe Most Shorted Stocks in June: Hold, Short, or Squeeze?Short interest is high and rising in many stocks, setting them up for a squeeze given the proper catalyst. The catalyst for a squeeze could be as simple as Meme stock mania and result in quick gains for savvy investors.June 18 at 7:25 AM | marketbeat.comThe Most Shorted Stocks in June: Hold, Short, or Squeeze? (TGTX)Given the proper catalyst, the short interest in these stocks may lead to a short squeeze. All the market needs is a push and it may come at any time.June 16 at 4:51 AM | marketbeat.com439,474 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Eventide Asset Management LLCEventide Asset Management LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 439,474 shares of the biopharmaceutical company's stock, valued atJune 15 at 5:31 AM | marketbeat.comOpaleye Management Inc. Purchases 325,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Opaleye Management Inc. lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 17.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,215,000 shares of the biophJune 13, 2024 | marketbeat.comParkwood LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Parkwood LLC reduced its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 85.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,347 shares of the biopharmaceutical company's stockJune 12, 2024 | seekingalpha.comHold TG Therapeutics For Intriguing OutcomesJune 11, 2024 | marketbeat.comLighthouse Investment Partners LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)Lighthouse Investment Partners LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 76,729 shares of the biopharmaceutical company's stock, valued at approximately $June 10, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Down 4.3% TG Therapeutics (NASDAQ:TGTX) Trading Down 4.3%June 7, 2024 | globenewswire.comTG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 5, 2024 | marketbeat.comRafferty Asset Management LLC Reduces Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Rafferty Asset Management LLC cut its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 33.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 571,126 shares of the biopharmaceutical company's stock after sellingJune 4, 2024 | marketbeat.comNorges Bank Makes New $18.36 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)Norges Bank bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,075,037 shares of the biopharmaceutical company's stock,June 3, 2024 | globenewswire.comTG Therapeutics to Participate in the Jefferies Global Healthcare ConferenceJune 3, 2024 | marketbeat.comUBS Group AG Has $9.65 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)UBS Group AG grew its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 564,836 shares of the biopharmaceutical company's stock after buying anJune 2, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Corient Private Wealth LLCCorient Private Wealth LLC boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 231.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 93,381 shares of the biopharmaceutical company's stock after acquiring an additional 65May 31, 2024 | globenewswire.comTG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingMay 28, 2024 | globenewswire.comTG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingMay 20, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Stock Position Reduced by BNP Paribas Financial MarketsBNP Paribas Financial Markets decreased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 74.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 293,607 shares of the biopharmacMay 17, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Down 4.1% TG Therapeutics (NASDAQ:TGTX) Stock Price Down 4.1%May 3, 2024 | seekingalpha.comTG Therapeutics: Less Room For Doubt About BriumviMay 3, 2024 | finance.yahoo.comTG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comFY2025 EPS Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX) Decreased by AnalystTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley decreased their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research note issued to investors on Wednesday, May 1st. B. Riley analyst M. Mamtani now anticipates that the biopharmaMay 3, 2024 | fool.comWhy TG Therapeutics Stock Was Rocketing Higher This WeekMay 3, 2024 | finance.yahoo.comRainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More OptimisticMay 2, 2024 | markets.businessinsider.comSell Rating on TG Therapeutics: Caution Amid Competitive Threats and Decelerating Prescription GrowthMay 2, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Price Target Raised to $49.00 at HC WainwrightHC Wainwright boosted their target price on TG Therapeutics from $45.00 to $49.00 and gave the stock a "buy" rating in a research report on Thursday.May 2, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Releases Earnings Results, Misses Estimates By $0.02 EPSTG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The firm's quarterly revenue was up 713.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.28) EPS.May 2, 2024 | finance.yahoo.comTG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 2, 2024 | marketbeat.comQ2 2024 EPS Estimates for TG Therapeutics, Inc. Raised by B. Riley (NASDAQ:TGTX)TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley upped their Q2 2024 earnings estimates for shares of TG Therapeutics in a report issued on Tuesday, April 30th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings per sMay 2, 2024 | gurufocus.comQ1 2024 TG Therapeutics Inc Earnings Call TranscriptMay 1, 2024 | markets.businessinsider.comHold Rating on TG Therapeutics Amidst Strong Briumvi Launch and Competitive Market PressuresMay 1, 2024 | marketwatch.comTG Therapeutics Shares Rise 27% After 1Q Revenue BeatMay 1, 2024 | markets.businessinsider.comTG Therapeutics Inc. Q1 Loss decreases, but misses estimatesMay 1, 2024 | msn.comTG Therapeutics jumps as Q1 Briumvi sales top guidanceMay 1, 2024 | finance.yahoo.comTG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net LossMay 1, 2024 | marketbeat.comTG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders acquired 13,983 call options on the company. This is an increase of 88% compared to the average daily volume of 7,433 call options.May 1, 2024 | investorplace.comTGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Forecasted to Post FY2026 Earnings of $1.60 Per ShareTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley cut their FY2026 earnings estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, April 30th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earninMay 1, 2024 | globenewswire.comTG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsApril 30, 2024 | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business UpdateApril 23, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)April 18, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%TG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%April 18, 2024 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Earns "Overweight" Rating from JPMorgan Chase & Co.JPMorgan Chase & Co. reiterated an "overweight" rating and issued a $25.00 price target on shares of TG Therapeutics in a research note on Thursday.April 18, 2024 | globenewswire.comTG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingApril 18, 2024 | globenewswire.comTG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple SclerosisApril 17, 2024 | seekingalpha.comTG Therapeutics: The Cloud Over BriumviApril 15, 2024 | msn.comTG Posts Gains on Results of MS Drug TestApril 15, 2024 | globenewswire.comTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingApril 15, 2024 | globenewswire.comTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingApril 14, 2024 | nasdaq.comTG Therapeutics Breaks Below 200-Day Moving Average - Notable for TGTXApril 14, 2024 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from BrokeragesTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the compan Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address why 99.94% won’t make you money (Ad)I believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them. Click here to download my options trading cheat sheet (5-7 stocks inside here) TGTX Media Mentions By Week TGTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼1.310.91▲Average Medical News Sentiment TGTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼64▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Deciphera Pharmaceuticals News Sage Therapeutics News FibroGen News Catalent News Insmed News Elanco Animal Health News Roivant Sciences News Legend Biotech News Cerevel Therapeutics News Ascendis Pharma A/S News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | Sponsored